March 31, 2015


Thrasos Therapeutics Raises $21M, Advances Drug to Prevent Acute Kidney Injury

Thrasos Therapeutics Inc. has raised a $21 million Series D financing to make acute kidney injury a less-common complication of heart surgery.

Acute kidney injury can lead to increased risk of illness and death, according to the National Kidney Foundation . It occurs in 20% to 25% of cardiac surgeries, Thrasos Chief Executive Richard Andrews said. Some cardiac-surgery patients are at even higher risk, including the elderly and people who already have chronic kidney disease, he said....

Read more: